UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~March 25~~April 14, 2025

Mural Oncology plc

(Exact name of Registrant as Specified in Its Charter)

Ireland	001-41837	98-1748617
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
10 Earlsfort Terrace
Dublin 2, D02 T380, Ireland		Not Applicable
(Address of Principal Executive Offices)		(Zip Code)

10 Earlsfort Terrace Dublin 2, D02 T380, Ireland		Not Applicable
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: +353-1-905-8020

Registrant’s Telephone Number, Including Area Code: +353- 1-905-8020

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Ordinary Shares, nominal value $0.01

MURA

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.05.

Costs Associated with Exit or Disposal Activities.

On April 14, 2025, the board of directors (the “Board”) of Mural Oncology plc (the “Company”) determined to discontinue all clinical development of nemvaleukin alfa and, in connection with such decision, approved a reduction in the Company’s workforce by approximately 104 positions, or approximately 90% (the “Reduction”).

The Company expects to substantially complete the Reduction by the end of the second quarter of 2025. The Company expects to incur costs of approximately $9.0 million to $10.0 million related to the Reduction, primarily consisting of severance payments and employee benefit costs. Additionally, the Company expects to incur $2.0 million to $4.0 million in non-cash impairment charges associated with property and equipment expected to be sold or otherwise disposed of. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Reduction. The costs related to the Reduction are expected to be substantially incurred in the second quarter of 2025. The estimated costs that the Company expects to incur and the estimated timing to complete the Reduction and for the incurrence of the costs are subject to a number of assumptions, and actual results may differ materially from these estimates.

Item 8.01.

Other Events.

On ~~March~~April 2515, 2025, ~~Mural Oncology plc (~~the “Company”) ~~announced~~issued ~~that~~a ~~the~~press ~~ARTISTRY-7~~release ~~phase~~announcing 3that ~~trial~~following review of ~~nemvaleukin~~data ~~alfa~~from inits ~~combination~~phase ~~with~~2 ~~Merck’s~~ARTISTRY-6 ~~(known~~trial asin ~~MSD~~melanoma ~~outside the US~~ and ~~Canada)~~previously ~~anti-PD-1~~announced ~~therapy,~~results ~~KEYTRUDA®~~from ~~(“pembrolizumab”),~~the ~~versus~~phase ~~investigator’s~~3 ~~choice~~ARTISTRY-7 ~~chemotherapy~~trial in ~~patients with~~ platinum-resistant ovarian cancer, ~~(“PROC”)~~the ~~will~~Company ~~not~~is ~~continue~~discontinuing toall ~~final~~clinical ~~analysis~~development of nemvaleukin alfa and ~~the~~plans ~~Company~~to ~~will~~immediately ~~cease~~commence ~~development~~the exploration of ~~nemvaleukin~~strategic ~~for~~alternatives ~~PROC.~~focused Inon ~~the~~maximizing ~~pre-specified~~shareholder ~~interim~~value. ~~analysis~~The ~~conducted~~Company byhas ~~the~~engaged ~~independent~~Lucid ~~data~~Capital ~~monitoring committee~~Markets, ~~nemvaleukin~~LLC into ~~combination~~act ~~with~~as ~~pembrolizumab~~its ~~did~~financial ~~not~~advisor ~~achieve~~in aconnection ~~statistically~~with ~~significant~~the ~~improvement~~exploration inof ~~overall~~strategic ~~survival~~alternatives. ~~versus~~There ~~investigator’s~~can ~~choice~~be ~~chemotherapy~~no ~~alone~~assurance ~~and~~that the ~~Company~~exploration ~~believes~~of ~~the~~strategic ~~study~~alternatives iswill ~~highly~~result ~~unlikely~~in tothe ~~achieve~~Company ~~success~~pursuing ata ~~the~~transaction ~~final~~or ~~analysis.~~that ~~Median~~any ~~overall~~acquisition ~~survival~~or ~~was~~other ~~10.1~~transaction ~~months~~involving ~~for~~the ~~patients~~Company ~~treated~~will ~~with~~be ~~nemvaleukin~~completed, innor ~~combination~~as ~~with~~to ~~pembrolizumab~~the ~~and~~terms ~~9.8~~on ~~months~~which ~~for~~any ~~patients~~acquisition ~~treated~~or ~~with~~other ~~investigator’s~~transaction ~~choice~~will ~~chemotherapy~~occur, ~~(hazard~~if ~~ratio:~~at 0all.~~98).~~

Nemvaleukin has a well characterized and favorable safety profile, both as a monotherapy and in combination with pembrolizumab, with over 800 patients treated across the broader clinical program. In the interim analysis of ARTISTRY-7, the safety profile was generally consistent with previously reported data.

Nemvaleukin is currently being evaluated in a potentially registrational, phase 2 trial, ARTISTRY-6, cohort 2 in mucosal melanoma, with a topline data readout expected in the second quarter of 2025. Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma are expected in the second quarter of 2025 for cohort 3 of ARTISTRY-6 (monotherapy) and the second half of 2025 for cohort 4 of ARTISTRY-6 (combination therapy), subject to patient enrollment.

ARTISTRY-7 is a phase 3 trial comparing nemvaleukin in combination with pembrolizumab vs. investigator choice single agent chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, with a primary endpoint of overall survival. This four-arm trial also contains two smaller single agent arms, a pembrolizumab and a nemvaleukin arm, to assess contribution of components. A total of 456 patients were enrolled over the four arms of the trial in an approximate 3:1:1:3 randomization. Only arms 1 (nemvaleukin in combination with pembrolizumab) and 4 (investigator’s choice chemotherapy) were designed to be assessed for statistical comparisons. The pre-specified interim analysis was conducted at 77% of events (219 events) needed for the final analysis.

Forward Looking Statements

Statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the ~~Company~~company’s ~~pipeline~~exploration and ~~development~~review ~~programs, including the expected timing~~ of ~~data~~strategic ~~readouts from the ARTISTRY-6 trial~~alternatives, ~~the~~its ~~potential~~ability ofto ~~the~~identify ~~Company’s product candidates~~ and ~~programs~~complete toa ~~address~~transaction ~~unmet~~as ~~medical~~a ~~needs,~~result ~~the continued progress~~ of the ~~Company’s~~strategic ~~pipeline~~alternatives ~~and~~process ~~programs,~~ and the ~~sufficiency~~Reduction ofand the ~~Company’s~~related ~~cash resources for the period anticipated~~costs. Any forward-looking statements in this Current Report are based on ~~the Company~~management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include, among others, the inherent risks and uncertainties associated with competitive developments, preclinical development, clinical trials, recruitment of patients, product development activities and regulatory approval requirements; that preclinical or interim results and data from ongoing clinical studies of the Companycompany’s ~~cytokine~~ability ~~programs~~to ~~and~~successfully ~~product~~pursue ~~candidates~~a ~~may~~strategic ~~not~~alternative betransaction ~~predictive~~on ofattractive ~~future or final results from such studies~~terms, ~~results of future clinical studies~~ or ~~real-world results; future clinical trials or future stages of ongoing clinical trials may not be initiated or completed on time or~~ at all; ~~the~~uncertainty ~~Company’s~~as ~~product candidates, including nemvaleukin, could be shown~~ to bewhether ~~unsafe~~the orReduction ~~ineffective;~~will ~~changes~~result in the ~~cost,~~anticipated ~~scope~~savings and ~~duration~~be ofcompleted ~~development~~when ~~activities~~anticipated; ~~the U.S. Food~~ and ~~Drug Administration may make adverse decisions regarding the Company’s product candidates; and~~ those other risks and uncertainties set forth in the ~~Company~~company’s filings with the Securities and Exchange Commission (“SEC”), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in subsequent filings the Company may make with the SEC. All forward-looking statements contained in this Current Report speak only as of the date of this Current Report. The Company anticipates that subsequent events and developments will cause its views to change. However, the Company undertakes no obligation to update such forward-looking statements to reflect events that occur or circumstances that exist after the date of this Current Report, except as required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Mural Oncology plc
Dated: March 25, 2025	By:	/s/ Maiken Keson-Brookes
Dated: April 15, 2025	By:	/s/ Maiken Keson-Brookes
	Name:	Maiken Keson-Brookes
	Title:	Chief Legal Officer

Filing Compare · Mural Oncology plc